APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
about
APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution.Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers.Diverse roles of RAD18 and Y-family DNA polymerases in tumorigenesis.Onset of deaminase APOBEC3B induction in response to DNA double-strand breaksThe therapeutic significance of mutational signatures from DNA repair deficiency in cancer
P2860
APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
@en
APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
@nl
type
label
APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
@en
APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
@nl
prefLabel
APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
@en
APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
@nl
P2093
P2860
P1433
P1476
APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
@en
P2093
Cyril H Benes
Michael S Lawrence
Rémi Buisson
P2860
P304
P356
10.1158/0008-5472.CAN-16-3389
P407
P577
2017-07-11T00:00:00Z